Saturated Iso-Type Fatty Acids from the Marine Bacterium Mesoflavibacter zeaxanthinifaciens with Anti-Trypanosomal Potential
-
Published:2024-04-13
Issue:4
Volume:17
Page:499
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Santos Ferreira Dayana Agnes1ORCID, de Castro Levatti Erica Valadares1, Santa Cruz Lucas Monteiro2ORCID, Costa Alan Roberto2, Migotto Álvaro E.3, Yamada Amanda Yaeko4, Camargo Carlos Henrique4ORCID, Christodoulides Myron5ORCID, Lago João Henrique G.6, Tempone Andre Gustavo1ORCID
Affiliation:
1. Pathophysiology Laboratory, Instituto Butantan, Av. Vital Brazil, 1500, Sao Paulo 05503-900, SP, Brazil 2. Centre of Organic Contaminants, Instituto Adolfo Lutz, Av. Dr. Arnaldo, 355, Sao Paulo 01246-000, SP, Brazil 3. Centre for Marine Biology, Universidade de São Paulo, Rodovia Doutor Manoel Hipólito do Rego, km. 131,5, Pitangueiras, Sao Sebastiao 11612-109, SP, Brazil 4. Centre of Bacteriology, Instituto Adolfo Lutz, Av. Dr. Arnaldo, 351, Sao Paulo 01246-000, SP, Brazil 5. Molecular Microbiology, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK 6. Centre of Natural Sciences and Humanities, Universidade Federal do ABC, Sao Paulo 09210-580, SP, Brazil
Abstract
Chagas disease is a Neglected Tropical Disease with limited and ineffective therapy. In a search for new anti-trypanosomal compounds, we investigated the potential of the metabolites from the bacteria living in the corals and sediments of the southeastern Brazilian coast. Three corals, Tubastraea coccinea, Mussismilia hispida, Madracis decactis, and sediments yielded 11 bacterial strains that were fully identified by MALDI-ToF/MS or gene sequencing, resulting in six genera—Vibrio, Shewanella, Mesoflavibacter, Halomonas, Bacillus, and Alteromonas. To conduct this study, EtOAc extracts were prepared and tested against Trypanosoma cruzi. The crude extracts showed IC50 values ranging from 15 to 51 μg/mL against the trypomastigotes. The bacterium Mesoflavibacter zeaxanthinifaciens was selected for fractionation, resulting in an active fraction (FII) with IC50 values of 17.7 μg/mL and 23.8 μg/mL against the trypomastigotes and amastigotes, respectively, with neither mammalian cytotoxicity nor hemolytic activity. Using an NMR and ESI-HRMS analysis, the FII revealed the presence of unsaturated iso-type fatty acids. Its lethal action was investigated, leading to a protein spectral profile of the parasite altered after treatment. The FII also induced a rapid permeabilization of the plasma membrane of the parasite, leading to cell death. These findings demonstrate that these unsaturated iso-type fatty acids are possible new hits against T. cruzi.
Funder
São Paulo Research State Foundation Conselho Nacional de Desenvolvimento Científico e Tecnológico
Reference46 articles.
1. Santos, J.D., Vitorino, I., Reyes, F., Vicente, F., and Lage, O.M. (2020). From Ocean to Medicine: Pharmaceutical Applications of Metabolites from Marine Bacteria. Antibiotics, 9. 2. Natural Products in Drug Discovery: Advances and Opportunities;Atanasov;Nat. Rev. Drug Discov.,2021 3. Smith, D., Buddie, A.G., Goss, R.J.M., Overmann, J., Lepleux, C., Brönstrup, M., Kloareg, B., Meiners, T., Brennecke, P., and Ianora, A. (2019). Discovery Pipelines for Marine Resources: An Ocean of Opportunity for Biotechnology?. World J. Microbiol. Biotechnol., 35. 4. Liang, J., She, J., Fu, J., Wang, J., Ye, Y., Yang, B., Liu, Y., Zhou, X., and Tao, H. (2023). Advances in Natural Products from the Marine-Sponge-Associated Microorganisms with Antimicrobial Activity in the Last Decade. Mar. Drugs, 21. 5. Overmann, J., and Lepleux, C. (2016). The Marine Microbiome: An Untapped Source of Biodiversity and Biotechnological Potential, Springer.
|
|